Kent David T, Carden Kelly A, Wang Li, Lindsell Christopher J, Ishman Stacey L
Department of Otolaryngology, Vanderbilt University Medical Center, Nashville, Tennessee.
Sleep Specialists, St Thomas Medical Partners, Nashville, Tennessee.
JAMA Otolaryngol Head Neck Surg. 2019 Nov 1;145(11):1044-1052. doi: 10.1001/jamaoto.2019.2723.
Hypoglossal nerve stimulation is a treatment option for patients with obstructive sleep apnea unable to tolerate continuous positive airway pressure. This study evaluates demographic factors that may be associated with greater improvements in postoperative outcomes of interest.
To examine the association of hypoglossal nerve stimulation with obstructive sleep apnea severity, daytime sleepiness, and sleep-related quality of life.
DESIGN, SETTING, AND PARTICIPANTS: Patient-level data were pooled from 3 prospective cohorts and 1 retrospective observational cohort comprising 584 adults with moderate to severe obstructive sleep apnea unable to tolerate or benefit from continuous positive airway pressure. The data were gathered from the Stimulation Therapy for Apnea Reduction Trial; a postmarket approval study conducted in Germany; the multicenter, international Adherence and Outcome of Upper Airway Stimulation for OSA Registry; and a retrospective cohort study from 2 sites in the United States.
Hypoglossal nerve stimulation.
Severity of obstructive sleep apnea was the primary outcome. The apnea-hypopnea index (AHI) (<5, normal; 5-15, mild; 15-30, moderate, and >30, severe) and Epworth Sleepiness Scale (range, 0-24; score >10 indicates pathologic sleepiness) outcomes were available at 2 to 6 months from 2 cohorts (n = 398), at 12 months from 1 cohort (n = 126), and at both times from 1 cohort (n = 60). Sleep-related quality of life and oxygen saturation nadir data were collected where available. Linear mixed-effects models were constructed to examine associations between clinical variables and reported postoperative outcomes at 6 and 12 months with study included as a random effect.
Of the 584 patients included in the study, 472 were men (80.8%); mean (SD) age was 58.5 (11.0) years. Greater improvement in the postoperative AHI was associated with a higher preoperative AHI (-0.74 events/h; 95% CI, -0.82 to -0.67), older patient age (-0.10 events/h; 95% CI, -0.20 to -0.00), and lower body mass index (0.52; 95% CI, 0.22-0.83). After adjusting for these variables and considering all patients in the analysis, the AHI was statistically higher at 12 months than at 6 months (3.24 events/h; 95% CI, 1.67-4.82 events/h).
Hypoglossal nerve stimulation demonstrated clinically significant improvements in obstructive sleep apnea severity, daytime sleepiness, and sleep-related quality of life in this pooled cohort of patient-level results. Age, body mass index, and preoperative AHI appeared to be associated with treatment outcomes, and these variables may explain some of the difference between 2- to 6-month and 12-month outcomes.
舌下神经刺激术是无法耐受持续气道正压通气的阻塞性睡眠呼吸暂停患者的一种治疗选择。本研究评估了可能与术后感兴趣结局有更大改善相关的人口统计学因素。
探讨舌下神经刺激术与阻塞性睡眠呼吸暂停严重程度、日间嗜睡及睡眠相关生活质量之间的关联。
设计、设置和参与者:患者水平的数据来自3个前瞻性队列和1个回顾性观察队列,共584名患有中度至重度阻塞性睡眠呼吸暂停且无法耐受或无法从持续气道正压通气中获益的成年人。数据来自减少呼吸暂停刺激治疗试验;在德国进行的一项上市后批准研究;多中心、国际性上气道刺激治疗阻塞性睡眠呼吸暂停的依从性和结局登记处;以及美国2个地点的一项回顾性队列研究。
舌下神经刺激术。
阻塞性睡眠呼吸暂停严重程度是主要结局。呼吸暂停低通气指数(AHI)(<5为正常;5 - 15为轻度;15 - 30为中度;>30为重度)和爱泼沃斯嗜睡量表(范围为0 - 24;得分>10表明存在病理性嗜睡)结局在2个队列(n = 398)的2至6个月、1个队列(n = 126)的12个月以及1个队列(n = 60)的两个时间点均可获得。在可行的情况下收集了睡眠相关生活质量和最低氧饱和度数据。构建线性混合效应模型以检验临床变量与6个月和12个月报告的术后结局之间的关联,并将研究作为随机效应纳入。
在纳入研究的584名患者中,472名是男性(80.8%);平均(标准差)年龄为58.5(11.0)岁。术后AHI的更大改善与术前更高的AHI(-0.74次/小时;95%置信区间,-0.82至-0.67)、患者年龄较大(-0.10次/小时;95%置信区间,-0.20至-0.00)以及较低的体重指数(0.52;95%置信区间,0.22 - 0.83)相关。在对这些变量进行调整并在分析中考虑所有患者后,1个月时的AHI在统计学上高于6个月时(3.24次/小时;95%置信区间,1.67 - 4.82次/小时)。
在这个汇集的患者水平结果队列中,舌下神经刺激术在阻塞性睡眠呼吸暂停严重程度、日间嗜睡及睡眠相关生活质量方面显示出临床上显著的改善。年龄、体重指数和术前AHI似乎与治疗结局相关,并且这些变量可能解释了2至6个月和12个月结局之间的一些差异。